These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32065790)

  • 21. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative Brain Amyloid Measures Predict Time-to-Progression from Amnestic Mild Cognitive Impairment to Alzheimer's Disease.
    Jun S; Kim H; Kim BS; Yoo BG; Lee WG;
    J Alzheimers Dis; 2019; 70(2):477-486. PubMed ID: 31256127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "And Does That Necessarily Mean Absolutely Alzheimer's?" An Analysis of Questions Raised Following Amyloid PET Results Disclosure.
    Kim JE; Tamres LK; Orbell SL; Cheng RZ; Klunk WE; Aizenstein HJ; Butters MA; McDade E; Lingler JH
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):45-54. PubMed ID: 37634955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient and caregiver reactions to clinical amyloid imaging.
    Grill JD; Cox CG; Kremen S; Mendez MF; Teng E; Shapira J; Ringman JM; Apostolova LG
    Alzheimers Dement; 2017 Aug; 13(8):924-932. PubMed ID: 28174068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study.
    Soleimani-Meigooni DN; Smith R; Provost K; Lesman-Segev OH; Allen IE; Chen MK; Cho H; Edwards L; Janelidze S; La Joie R; Mundada N; Ossenkoppele R; Stomrud E; Strandberg O; Strom A; Boxer AL; Dage JL; Gorno-Tempini ML; Kramer JH; Miller BL; Rojas JC; Rosen HJ; Lyoo CH; Hansson O; Rabinovici GD
    Ann Neurol; 2024 Sep; 96(3):476-487. PubMed ID: 38888212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.
    Weidman DA; Zamrini E; Sabbagh MN; Jacobson S; Burke A; Belden C; Powell J; Bhalla N; Roontiva A; Kuang X; Luo J; Chen K; Riggs G; Burke W
    Neurocase; 2017 Feb; 23(1):41-51. PubMed ID: 28376695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition.
    Tolbert S; Liu Y; Hellegers C; Petrella JR; Weiner MW; Wong TZ; Murali Doraiswamy P
    J Prev Alzheimers Dis; 2019; 6(4):274-282. PubMed ID: 31686100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
    Rabinovici GD; Gatsonis C; Apgar C; Chaudhary K; Gareen I; Hanna L; Hendrix J; Hillner BE; Olson C; Lesman-Segev OH; Romanoff J; Siegel BA; Whitmer RA; Carrillo MC
    JAMA; 2019 Apr; 321(13):1286-1294. PubMed ID: 30938796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.
    Beyer L; Brendel M; Scheiwein F; Sauerbeck J; Hosakawa C; Alberts I; Shi K; Bartenstein P; Ishii K; Seibyl J; Cumming P; Rominger A;
    J Alzheimers Dis; 2020; 74(1):101-112. PubMed ID: 31985461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
    Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
    JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.